Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2018 financial results conference call and Annual and Special Meeting of shareholders on...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that experienced healthcare executive Dr. Laurence Terrisse-Rulleau is being proposed for election to Cipher's...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Robert Tessarolo, President and Chief Executive Officer, will present at the 2018 Bloom Burton & Co....

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today provided a strategic and operational update and preliminary revenue results for the three months ended March 31, 2018. The...

Transaction broadens Cipher's Canadian dermatology portfolio with first and only prescription product for raised seborrheic keratoses (SKs) MISSISSAUGA, ON, April 6, 2018 /CNW/ - Cipher...

Cipher to Acquire Cardiome's Canadian Business Portfolio, Comprised of Four Commercial and Pipeline Assets Targeting Cardiovascular and Anti-Infective Indications for Upfront Consideration of...

90% increase in revenue and 214% increase in income from continuing operations for Q4 2017 Canadian launch of OZANEX™ in Jan 2018 Acquired Canadian rights to TRULANCE® in Feb 2018 MISSISSAUGA, ON,

A new differentiated treatment option for GI disorders Transaction broadens Cipher's Canadian portfolio providing entry into rapidly growing market where innovative treatments are needed...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q4 and full-year 2017 financial results conference call on Wednesday, February 28, 2018. Q4 AND...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it has entered into an exclusive distribution and supply agreement with Italmex Pharma S.A. ("Italmex") under which Cipher has granted Italmex...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced the Canadian launch of OZANEX™ (ozenoxacin cream, 1%), a novel bactericidal topical antibiotic cream indicated for the treatment of impetigo...

Substantially reduces cost of capital and interest expense, provides additional capacity to support future growth MISSISSAUGA, ON, Nov. 3, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH)...

Strong Q3 performance 29% revenue growth and 77% growth in income from continuing operations Production resumes at Puerto Rico manufacturing facilities MISSISSAUGA, ON, Nov. 3, 2017 /CNW/ - Cipher...

In the news release, Notice of Cipher Pharmaceuticals Q2 2017 conference call, issued today at 09:32, please note that an error occurred in the headline which should read "Notice of Cipher...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today commented on the impact from Hurricane Maria to its manufacturing partner's facilities in Puerto Rico. Galephar...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today commented on a warning letter issued to Cipher by the Office of Prescription Drug Promotion of the U.S. Food and Drug...

Company achieves important strategic milestones, delivers strong financial results MISSISSAUGA, ON, Aug. 11, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q2 2017 financial results conference call on Friday, August 11, 2017. Q2 2017 CONFERENCE CALL...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Chris Watters has joined the Company in the new position of Vice President, Corporate Development. Mr....

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual Meeting of Shareholders held...

Results highlighted by 92% increase in Adjusted EBITDA, 18% increase in revenue MISSISSAUGA, ON, May 11, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced the Health Canada approval of OZANEX™ (ozenoxacin cream, 1%) a novel topical antibiotic indicated for the treatment of impetigo in patients...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that it has completed an agreement (the "Agreement") to sell substantially all of the assets of Cipher...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2017 financial results conference call and Annual Meeting of shareholders on Thursday, May...

Mark Beaudet expected to be appointed new independent Chair of Board MISSISSAUGA, ON, April 12, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") announced today that it has completed an amendment to the securities purchase agreement (the "Amendment") with investment funds...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") announced today that veteran pharmaceutical industry executive Robert D. Tessarolo has been appointed President and Chief...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three and 12 months ended December 31, 2016. Unless otherwise noted,...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it will host a conference call its Q4 and full-year 2016 financial results on Thursday, March 2, 2017. Q4 AND YEAR-END 2016 CONFERENCE CALL...

Cipher Pharmaceuticals Inc. (TSX:CPH; NASDAQ:CPHR) ("Cipher" or "the Company") today announced that its Board of Directors has approved the voluntary withdrawal of its common shares from NASDAQ...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three months ended September 30, 2016. Unless otherwise...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Stephen L. Lemieux, Chief Financial Officer and Secretary of the Company, has been named Interim...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"), in response to a request for comment from Investment Industry Regulatory Organization of Canada ("IIROC") and an...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q3 2016 financial results on Friday, November 11, 2016. Q3 2016 CONFERENCE CALL WHEN:...

Company also announces appointment of Dr. John Mull as Chair of the Board of Directors MISSISSAUGA, ON, Sept. 1, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three months ended June 30, 2016. Unless otherwise...

Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher") today announced certain changes to its board of directors (the "Board"). As previously disclosed, a special committee of the Board...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced preliminary estimates of its financial results for the three months ended June 30, 2016. The complete...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q2 2016 financial results on Wednesday, August 10, 2016. Q2 2016 CONFERENCE CALL WHEN:...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that its New Drug Submission for Ozenoxacin has been accepted for review by Health Canada. Ozenoxacin...

A special committee (the "Special Committee") of the board of directors (the "Board") of Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher") responded today to an Early Warning Report...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Edesa Biotech Inc. ("Edesa") has licensed the rights to ASF-1096 (R-salbutamol) for use in...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at two upcoming...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual and Special...

- Revenue increased 23% - Delivered on multiple commercial and regulatory milestones - Positive cash from operating activities of $1.4 million while investing in future growth MISSISSAUGA, ON, May...

Product candidate may have the potential to transform tattoo removal process MISSISSAUGA, ON, May 2, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company")...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2016 financial results conference call and Annual and Special Meeting of...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Norm Evans, Chief Financial Officer, will be retiring from the Company. Mr. Evans will remain in...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Rosemary A. (Rose) Crane and Dr. Renee P. Tannenbaum, two pharmaceutical industry leaders, are...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has received Health Canada approvals for SD Cream and AD Cream (also known as Dermadexin and...